The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients

Cancer Research

Volumn 59, Issue 16, 1999, Pages 3980-3984

  Thavasu, Parames ^a   Propper, David ^b   McDonald, Alexander ^c   Dobbs, Nicola ^b   Ganesan, Trivadi ^b   Talbot, Dennis ^b   Braybrook, Jeremy ^b   Caponigro, Francesco ^c   Hutchison, Cathy ^c   Twelves, Christopher ^c   Man, Anthony ^d   Fabbro, Doriano ^d   Harris, Adrian ^b   Balkwill, Frances ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MIDOSTAURIN; PROTEIN KINASE C INHIBITOR;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CELL DIFFERENTIATION; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; DRUG EFFECT; ENZYME REGULATION; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS; TARGET CELL; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CYTOKINES; ENZYME INHIBITORS; HUMANS; LYMPHOCYTES; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASMS; PROTEIN KINASE C; STAUROSPORINE;

EID: 0033566983     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Caponigro, F., French, R. C., and Kaye, S. B. Protein kinase C: a worthwhile target for anticancer drugs? Anticancer Drugs, 8: 26-33, 1997.
2. Powis, G., and Alberts, D. S. Inhibiting intracellular signalling as a strategy for cancer chemoprevention. Eur. J. Cancer, 30A: 1138-1144, 1994.
3. Nishizuka, Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature (Lond.), 30S: 693-698, 1984.
4. Ikegami, Y., Yano, S., Nakao, K., Fujita, F., Sakamoto, Y., Murata, N., and Isowa, K. Antitumor activity of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on murine and human tumor models. Jpn. J. Pharmacol., 70: 65-72, 1996.
5. Mizuno, K., Saido, T. C., Ohno, S., Tamaoki, T., and Suzuki, K. Staurosporine-related compounds, K252a and UCN-01, inhibit both cPKC and nPKC. FEBS Lett., 330: 114-116, 1993.
6. Meyer, T., Regenass, U., Fabbro, D., Alteri, E., Rosel, J., Muller, M., Caravatti, G., and Matter, A. A derivative of staurosporine (CGP41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumour activity. Int. J. Cancer, 43: 851-856, 1989.
7. Geiges, D., Meyer, T., Marte, B., Vanek, M., Wessgerber, G. Pfeilschifter, J., Stabel, S., Fabbro, D., and Huwiler, A. Activation of protein kinase C subtypes α, γ, δ, ε,ζ and η by tumor-promoting and nontumor-promoting agents. Biochem. Pharmacol., 53: 865-875 1997.
8. van der Blick, A. M., and Borst, P. Multidrug resistance. Adv. Cancer Res., 52: 165-203, 1989.
9. Utz, I., Hofer, S., Regenass, U., Hilbe, W., Thaler, J., Grunicke, H., and Hofmann, J. The protein kinase C inhibitor CGP41251, a staurosporine derivative with antitumour activity, reverses multidrug resistance. Int. J. Cancer, 57: 104-110, 1994.
10. Budworth, J., Davies, R., Malkhandi, J., Gant, T. W., Ferry, D. R., and Gescher, A. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding of P-glycoprotein in multidrug resistant MCF-7/Adr cells. Br. J. Cancer, 73: 1063-1068, 1998.
11. Beltran, P. J., Fan, D., Fidler, I. J., and O'Brian, C. A. Chemosensitization of cancer cells by the staurosporine derivative CGP41251 in association with decreased P-glycoprotein phosphorylation. Biochem. Pharmacol., 53: 245-247, 1997.
12. Shapira, L., Takashiba, T., Champagne C., Amar S., and Van Dyke, T. E. Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-α and IL-1β production by human monocytes. J. Immunol., 153: 1818-1824, 1994.
13. Norris, J. G., Tang, L. P., Sparacio, S. M., and Benveniste, E. N. Signal transduction pathways mediating astrocyte IL-6 induction by IL-1β and tumour necrosis factor-α. J. Immunol., 152: 841-850, 1994.
14. Schonwasser, D. C., Marais, R. M., Marshall, C. J., and Parker, P. J. Activation of the mitogen-activated protein kinase/extracellular signal-related kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell. Biol., 18: 790-798, 1998.
15. Thavasu, P., Longhurst, S., Joel, S. P., Slevin, M., and Balkwill, F. R. Measuring cytokines in blood: the importance of anticoagulants, processing and storage. J. Immunol. Methods, 153: 115-124, 1992.
16. Zeger, S. L., and Liang, K. Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics, 42: 121-130, 1986.
17. Wilson, A. G., di Giovine, F. S., and Duff, G. W. Genetics of tumour necrosis factor a in autoimmune, infectious and neoplastic disease. J. Inflamm., 45: 1-12, 1995.
18. McDonald, A. C., Propper, D., King, D., Champain, K., Graf, P., Mann, A., Caponigro, F., Thavasu, P., Balkwill, F., Twelves, C., Kay, S. B., and Harris, A. L. Phase I and pharmacokinetic study of CGP 41251, and inhibitor of PKC. Proc. Am. Soc. Clin. Oncol. Annu. Meeting, 16: 212A, 1997.
19. Gearing, A. J., Beckett, P., Christodolou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., and Gordon, J. L. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature (Lond.), 370: 555-557, 1994.
20. Zhang, W., Dziak, R. M., and Aletta, J. M. EGF-mediated phosphorylation of extracellular signal-regulated kinases in osteoblastic cells. J. Cell. Physiol., 162: 348-358, 1995.